- Waldenstrom macroglobulinemia (WM) is a slow-growing type of non-Hodgkin lymphoma (NHL). The cancer cells make large amounts of an abnormal protein (a macroglobulin called IgM) in the blood.
- WM is most often caused by mutations in the MYD88 genes; about 30-40% of patients also have a mutation in the CXCR4 gene.
- X4 Pharmaceuticals is conducting a Phase 1b clinical trial, as part of a collaboration with The Leukemia & Lymphoma Society, to evaluate the study drug, mavorixafor, in combination with the marketed drug ibrutinib in patients with both MYD88 and CXCR4 mutations.
- WMtrial.com –learn more about the study, criteria and how to enroll at this X4 study website
- ClinicalTrials.gov –listing for the X4 study (NCT Identifier: 04274738) contains study sites and contact information
- The International Waldenstrom’s Macroglobulinemia Foundation provides support, education to people living with WM. Includes a toolkit for newly diagnosed, events, and news.